AC Immune Stock Price, News & Analysis

AC Immune SA (NASDAQ: ACIU) announced its participation in the UBS Global Healthcare Virtual Conference on May 26, 2021, and the Jefferies Virtual Healthcare Conference from June 2-4, 2021. CEO Prof. Andrea Pfeifer will present the company’s strategy and Alzheimer’s disease vaccine programs targeting phospho-Tau and Abeta. Webcasts of the events will be available on AC Immune’s website. The company focuses on precision medicine for neurodegenerative diseases, holding a diversified pipeline with six clinical trials ongoing.

AC Immune (NASDAQ: ACIU) announced the expansion of its Phase 1b/2a clinical trial of the ACI-35.030 vaccine for Alzheimer's disease, following encouraging interim results. Vaccination at the second highest dose cohort will proceed, while the highest dose group continues to be evaluated, with initial results expected in Q4 2021. The trial aims to assess safety, tolerability, and immunogenicity of the vaccine candidates ACI-35.030 and JACI-35.054, both targeting phosphorylated Tau proteins. Encouraging data reported includes a 100% antibody response in early Alzheimer’s patients.

AC Immune SA (NASDAQ: ACIU) reported potent interim results for its anti-pTau Alzheimer’s vaccine in a Phase 1b/2a study and initiated a first-in-human study for a new alpha-synuclein PET diagnostic.

The company maintains a robust cash position of CHF 216.1 million, ensuring funding through at least Q1 2024. However, it recorded a net loss of CHF 16.7 million for Q1 2021, a significant increase from CHF 7.7 million in the previous year. The decrease in contract revenues by CHF 12.3 million mainly contributed to this loss, highlighting challenges in generating income.

AC Immune SA (NASDAQ: ACIU) has appointed Dr. Alan Colowick to its Board of Directors, enhancing its leadership in precision medicine for neurodegenerative diseases. Dr. Colowick brings over 20 years of experience in biotech, having served in executive roles at notable companies such as Celgene and Amgen, and as a Partner at Sofinnova Investments. His expertise is expected to strengthen AC Immune's pipeline, which features nine therapeutic and three diagnostic candidates, with six currently undergoing clinical trials. The appointment is seen as a pivotal move for the company's growth and strategic development.

AC Immune SA (NASDAQ: ACIU) hosted an investor webinar on March 31, 2021, highlighting its innovative Morphomer™ technology platform aimed at developing therapeutics and diagnostics for neurodegenerative diseases. CEO Prof. Andrea Pfeifer emphasized the platform's ability to create first-in-class candidates targeting key proteins like Tau and TDP-43. Notable financial achievements include over CHF 174 million from strategic partnerships. The webinar also showcased advancements in clinical validation of Morphomer candidates, including the Phase 1 study success of candidate ACI-3024.

AC Immune, a clinical-stage biopharmaceutical company, will host a corporate update webinar on March 31, 2021, from 10:00 AM to 11:30 AM ET. The focus will be on the company’s innovative Morphomer™ technology for developing targeted therapies for neurodegenerative diseases. The current pipeline includes two clinical-stage diagnostic candidates and one therapeutic candidate that has completed Phase 1. Key speakers will include CEO Andrea Pfeifer and CSO Marie Kosco-Vilbois, among others. This event will include an interactive Q&A session with the audience.

AC Immune SA (NASDAQ: ACIU) announced positive interim results from its Phase 1b/2a study of the anti-pTau Alzheimer's vaccine, demonstrating strong safety and immune responses. The financial update revealed a cash position of CHF 225.9 million, sufficient to sustain operations into Q1 2024. However, contract revenues decreased significantly from CHF 110.5 million in 2019 to CHF 15.4 million in 2020, primarily due to reduced milestone payments. The company anticipates 2021 cash burn between CHF 65 million and CHF 75 million, while further clinical data is expected in Q2.

AC Immune (NASDAQ: ACIU) reported promising Phase 1b results for its novel anti-amyloid-beta vaccine at a global Down syndrome symposium. The vaccine, ACI-24, demonstrated significant immunogenicity and safety, with no serious adverse events recorded. The trial achieved a high retention rate and showed positive pharmacodynamic responses. The company plans to advance the vaccine into mid-stage clinical trials for treating Alzheimer's disease related to Down syndrome, while optimizing its formulation based on encouraging preclinical data.

AC Immune SA (NASDAQ: ACIU) has showcased innovative findings at the AD/PD 2021 conference, focusing on therapies targeting alpha-synuclein and TDP-43, associated with neurodegenerative diseases. Highlights include first-in-class PET tracers and antibody candidates demonstrating significant in vivo actions. The alpha-synuclein program is anticipated to yield first clinical results by Q3 2021, potentially enabling precise disease diagnostics and tailored therapies. With a robust pipeline and strategic collaborations, AC Immune aims to lead in precision medicine for neurodegenerative conditions.